Varma Mutual Pension Insurance Co Buys 9,300 Shares of Boston Scientific Corporation $BSX
by Amy Steele · The Cerbat GemVarma Mutual Pension Insurance Co raised its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 3.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 280,181 shares of the medical equipment provider’s stock after purchasing an additional 9,300 shares during the quarter. Varma Mutual Pension Insurance Co’s holdings in Boston Scientific were worth $26,715,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Avidian Wealth Enterprises LLC lifted its position in shares of Boston Scientific by 45.0% in the 4th quarter. Avidian Wealth Enterprises LLC now owns 5,563 shares of the medical equipment provider’s stock worth $530,000 after purchasing an additional 1,727 shares during the period. Long Run Wealth Advisors LLC lifted its position in shares of Boston Scientific by 1.5% in the 4th quarter. Long Run Wealth Advisors LLC now owns 40,224 shares of the medical equipment provider’s stock worth $3,835,000 after purchasing an additional 605 shares during the period. Intact Investment Management Inc. lifted its position in shares of Boston Scientific by 15.9% in the 4th quarter. Intact Investment Management Inc. now owns 15,300 shares of the medical equipment provider’s stock worth $1,459,000 after purchasing an additional 2,100 shares during the period. Core Alternative Capital lifted its position in shares of Boston Scientific by 3,122.9% in the 4th quarter. Core Alternative Capital now owns 1,547 shares of the medical equipment provider’s stock worth $148,000 after purchasing an additional 1,499 shares during the period. Finally, Oak Harbor Wealth Partners LLC lifted its position in shares of Boston Scientific by 9.2% in the 4th quarter. Oak Harbor Wealth Partners LLC now owns 6,686 shares of the medical equipment provider’s stock worth $638,000 after purchasing an additional 565 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.
Boston Scientific Stock Up 0.3%
Shares of NYSE:BSX opened at $56.64 on Monday. The business’s 50 day simple moving average is $67.06 and its two-hundred day simple moving average is $84.57. The firm has a market cap of $84.18 billion, a P/E ratio of 23.70, a PEG ratio of 1.04 and a beta of 0.62. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a 52-week low of $56.05 and a 52-week high of $109.50.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on BSX. Truist Financial dropped their price target on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. BTIG Research lowered their price objective on Boston Scientific from $90.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. JPMorgan Chase & Co. lowered their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Canaccord Genuity Group lowered their price objective on Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $93.91.
Get Our Latest Report on Boston Scientific
Boston Scientific Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Read More
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).